

Gaetano Finocchiaro

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8896376/gaetano-finocchiaro-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

151
papers

14,111
citations

49
h-index

118
g-index

164
ext. papers

17,397
ext. citations

9.6
avg, IF

5.47
L-index

#	Paper	IF	Citations
151	Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter.. <i>Neuro-Oncology</i> , 2022 ,	1	8
150	ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. <i>Cell Reports</i> , 2021 , 36, 109455	10.6	2
149	High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 831-842	7.4	8
148	Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling. <i>Cancer Immunology Research</i> , 2021 , 9, 441-453	12.5	7
147	A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors. <i>Oncologist</i> , 2021 , 26, e2254-e2264	5.7	2264
146	PGE Is Crucial for the Generation of FAST Whole- Tumor-Antigens Loaded Dendritic Cells Suitable for Immunotherapy in Glioblastoma. <i>Pharmaceutics</i> , 2020 , 12,	6.4	2
145	Simultaneous Detection of , , and Gene Mutations by Targeted NGS in an Italian Cohort of Suspected NF1 Patients. <i>Genes</i> , 2020 , 11,	4.2	1
144	In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting. <i>Neurological Sciences</i> , 2020 , 41, 347-355	3.5	7
143	Actinomycin D: a new opening for an old drug. <i>Neuro-Oncology</i> , 2020 , 22, 1235-1236	1	1
142	Milan 2020: COVID-19, neuro-oncology and much more. <i>Journal of Neuro-Oncology</i> , 2020 , 148, 201-202	4.8	1
141	B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. <i>EBioMedicine</i> , 2019 , 47, 33-43	8.8	45
140	Allergic Signs in Glioma Pathology: Current Knowledge and Future Perspectives. <i>Cancers</i> , 2019 , 11,	6.6	4
139	NG2/CSPG4 in glioblastoma: about flexibility. <i>Neuro-Oncology</i> , 2019 , 21, 697-698	1	4
138	The landscape of the mesenchymal signature in brain tumours. <i>Brain</i> , 2019 , 142, 847-866	11.2	120
137	Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy. <i>Neuro-Oncology Advances</i> , 2019 , 1, vdz022	0.9	8
136	Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment Against Glioblastoma. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	7
135	ABCC3 Expressed by CD56 CD16 NK Cells Predicts Response in Glioblastoma Patients Treated with Combined Chemotherapy and Dendritic Cell Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	9

134	Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotype-Phenotype Correlations in A Large Independent Cohort. <i>Cancers</i> , 2019 , 11,	6.6	9
133	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019 , 576, 112-120	50.4	151
132	Neurological malignancies in neurofibromatosis type 1. <i>Current Opinion in Oncology</i> , 2019 , 31, 554-561	4.2	4
131	Altered function of the glutamate-aspartate transporter GLAST, a potential therapeutic target in glioblastoma. <i>International Journal of Cancer</i> , 2019 , 144, 2539-2554	7.5	13
130	The molecular landscape of glioma in patients with Neurofibromatosis 1. <i>Nature Medicine</i> , 2019 , 25, 176-187	5.8	88
129	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. <i>Oncologist</i> , 2019 , 24, 521-528	5.7	28
128	Constitutive and TNF β Inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	67
127	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. <i>Neuro-Oncology</i> , 2018 , 20, 873-884	1	63
126	Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8 T cell activation in the presence of adjuvant temozolomide. <i>OncImmunology</i> , 2018 , 7, e1412901	7.2	34
125	Fibronectin-adherent peripheral blood derived mononuclear cells as Paclitaxel carriers for glioblastoma treatment: An in vitro study. <i>Cytotherapy</i> , 2017 , 19, 721-734	4.8	8
124	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017 , 31, 737-754.e6	24.3	511
123	TLRgeting Evasion of Immune Pathways in Glioblastoma. <i>Cell Stem Cell</i> , 2017 , 20, 422-424	18	12
122	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O-Methylguanine-DNA Methyltransferase Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017 , 35, 343-351	2.2	77
121	MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives. <i>Journal of Immunology Research</i> , 2017 , 2017, 5813951	4.5	42
120	Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis. <i>Quantitative Imaging in Medicine and Surgery</i> , 2017 , 7, 592-597	3.6	3
119	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 1373-1385	21.7	518
118	Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor. <i>Stem Cells</i> , 2017 , 35, 2218-2228	5.8	30
117	Identification and characterization of a new source of adult human neural progenitors. <i>Cell Death and Disease</i> , 2017 , 8, e2991	9.8	9

116	Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - AuthorsPreply. <i>Lancet Oncology, The</i> , 2017 , 18, e709-e710	21.7	4
115	Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. <i>Cancer Cell</i> , 2017 , 32, 42-56.e6	24.3	680
114	Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. <i>Oncotarget</i> , 2017 , 8, 55575-55581	3.3	9
113	Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature. <i>Neurosurgical Review</i> , 2016 , 39, 37-45; discussion 45-6	3.9	32
112	Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. <i>Cell</i> , 2016 , 167, 1281-1295.e18	56.2	155
111	Resetting cancer stem cell regulatory nodes upon MYC inhibition. <i>EMBO Reports</i> , 2016 , 17, 1872-1889	6.5	33
110	A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways. <i>Nature Communications</i> , 2016 , 7, 12885	17.4	51
109	Ultrasonic Surgical Aspirate is a Reliable Source For Culturing Glioblastoma Stem Cells. <i>Scientific Reports</i> , 2016 , 6, 32788	4.9	7
108	Clonal evolution of glioblastoma under therapy. <i>Nature Genetics</i> , 2016 , 48, 768-76	36.3	390
107	The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma. <i>Onc Immunology</i> , 2016 , 5, e1108513	7.2	17
106	Principles of immunotherapy. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 134, 163-81	3	7
105	Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 101-9	7.4	35
104	MET inhibition overcomes radiation resistance of glioblastoma stem-like cells. <i>EMBO Molecular Medicine</i> , 2016 , 8, 550-68	12	54
103	ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2016 , 18, vi17-vi18	1	29
102	AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016 , 18, 1304-12	1	53
101	Human glioblastoma stem-like cells accumulate protoporphyrin IX when subjected to exogenous 5-aminolaevulinic acid, rendering them sensitive to photodynamic treatment. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2016 , 163, 203-10	6.7	17
100	EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	31
99	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015 , 372, 2481-98	59.2	1828

98	Radiosurgery reirradiation for high-grade glioma recurrence: a retrospective analysis. <i>Neurological Sciences</i> , 2015 , 36, 1431-40	3.5	23
97	Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. <i>Acta Neuropathologica Communications</i> , 2015 , 3, 4	7.3	73
96	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology, The</i> , 2015 , 16, e534-e542	21.7	425
95	Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients. <i>Stem Cells Translational Medicine</i> , 2015 , 4, 1164-72	6.9	14
94	VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015 , 121, 499-504	4.8	26
93	126 novel mutations in Italian patients with neurofibromatosis type 1. <i>Molecular Genetics & Genomic Medicine</i> , 2015 , 3, 513-25	2.3	22
92	Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. <i>Clinical Cancer Research</i> , 2015 , 21, 3307-17	12.9	176
91	Novel mechanisms and approaches in immunotherapy for brain tumors. <i>Discovery Medicine</i> , 2015 , 20, 7-15	2.5	8
90	Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. <i>Neuro-Oncology</i> , 2014 , 16, 719-27	1	53
89	TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. <i>British Journal of Cancer</i> , 2014 , 111, 2024-32	8.7	126
88	Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. <i>Neurology</i> , 2014 , 83, 1200-6	6.5	142
87	Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma. <i>Cancer Research</i> , 2014 , 74, 1833-44	10.1	75
86	Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: a phantom study. <i>Physica Medica</i> , 2014 , 30, 702-7	2.7	18
85	Perspectives for immunotherapy in glioblastoma treatment. <i>Current Opinion in Oncology</i> , 2014 , 26, 608-142	14.2	23
84	The Somatic Genomic Landscape of Glioblastoma. <i>Cell</i> , 2014 , 157, 753	56.2	29
83	Association of increased progression-free survival in primary glioblastomas with lymphopenia at baseline and activation of NK and NKT cells after dendritic cell immunotherapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2087-2087	2.2	1
82	Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan. <i>PLoS ONE</i> , 2014 , 9, e90535	3.7	14
81	A subpopulation of circulating endothelial cells express CD109 and is enriched in the blood of cancer patients. <i>PLoS ONE</i> , 2014 , 9, e114713	3.7	13

80	The integrated landscape of driver genomic alterations in glioblastoma. <i>Nature Genetics</i> , 2013 , 45, 1141-96.3	36.3	400
79	The somatic genomic landscape of glioblastoma. <i>Cell</i> , 2013 , 155, 462-77	56.2	2900
78	Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres. <i>Molecular Cancer</i> , 2013 , 12, 160	42.1	10
77	Operability of glioblastomas: "sins of action" versus "sins of non-action". <i>Neurological Sciences</i> , 2013 , 34, 2107-16	3.5	8
76	DNA damage in mammalian neural stem cells leads to astrocytic differentiation mediated by BMP2 signaling through JAK-STAT. <i>Stem Cell Reports</i> , 2013 , 1, 123-38	8	62
75	The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. <i>Oncolmmunology</i> , 2013 , 2, e23401	7.2	42
74	Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. <i>PLoS ONE</i> , 2013 , 8, e74345	3.7	21
73	Expression profile of frizzled receptors in human medulloblastomas. <i>Journal of Neuro-Oncology</i> , 2012 , 106, 271-80	4.8	10
72	Central nervous system lymphoma occurring in a patient with neurofibromatosis type 1 (von Recklinghausen disease). <i>Neurological Sciences</i> , 2012 , 33, 1429-33	3.5	1
71	A radial glia gene marker, fatty acid binding protein 7 (FABP7), is involved in proliferation and invasion of glioblastoma cells. <i>PLoS ONE</i> , 2012 , 7, e52113	3.7	69
70	Rai is a new regulator of neural progenitor migration and glioblastoma invasion. <i>Stem Cells</i> , 2012 , 30, 817-32	5.8	28
69	Transforming fusions of FGFR and TACC genes in human glioblastoma. <i>Science</i> , 2012 , 337, 1231-5	33.3	567
68	The MET oncogene is a functional marker of a glioblastoma stem cell subtype. <i>Cancer Research</i> , 2012 , 72, 4537-50	10.1	104
67	FABP4 is a candidate marker of cerebellar liponeurocytomas. <i>Journal of Neuro-Oncology</i> , 2012 , 108, 513-28	4.8	23
66	Immunotherapy against the radial glia marker GLAST effectively triggers specific antitumor effectors without autoimmunity. <i>Oncolmmunology</i> , 2012 , 1, 884-893	7.2	16
65	An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma. <i>PLoS ONE</i> , 2012 , 7, e52301	3.7	27
64	NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. <i>Oncotarget</i> , 2012 , 3, 723-34	3.4	69
63	FOXP3, a novel glioblastoma oncosuppressor, affects proliferation and migration. <i>Oncotarget</i> , 2012 , 3, 1146-57	3.3	18

62	Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1759-74	3.5	22
61	Immunotherapy for glioma: getting closer to the clinical arena?. <i>Current Opinion in Neurology</i> , 2011 , 24, 641-7	7.1	26
60	Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. <i>Neuropathology and Applied Neurobiology</i> , 2011 , 37, 381-94	5.2	106
59	A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 1739-50	7.4	33
58	DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence. <i>Oncologist</i> , 2011 , 16, 1440-50	5.7	19
57	Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. <i>Neuro-Oncology</i> , 2010 , 12, 377-88	1	28
56	High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. <i>Molecular Cancer Research</i> , 2009 , 7, 665-77	6.6	78
55	Genetic signature of adult gliomas and correlation with MRI features. <i>Expert Review of Molecular Diagnostics</i> , 2009 , 9, 709-20	3.8	11
54	Reelin affects chain-migration and differentiation of neural precursor cells. <i>Molecular and Cellular Neurosciences</i> , 2009 , 42, 341-9	4.8	28
53	A role for the transcription factor HEY1 in glioblastoma. <i>Journal of Cellular and Molecular Medicine</i> , 2009 , 13, 136-46	5.6	56
52	Dendritic cell vaccines for cancer stem cells. <i>Methods in Molecular Biology</i> , 2009 , 568, 233-47	1.4	17
51	Principi di terapia genica 2009 , 593-606		
50	Radiation-induced glioblastoma in a medulloblastoma patient: a case report with molecular features. <i>Neuropathology</i> , 2008 , 28, 633-9	2	16
49	Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. <i>Neuro-Oncology</i> , 2008 , 10, 79-87	1	136
48	Loss of heterozygosity studies in extracranial metastatic meningiomas. <i>Journal of Neuro-Oncology</i> , 2007 , 85, 81-5	4.8	12
47	Expression of the neurogenic basic helix-loop-helix transcription factor NEUROG1 identifies a subgroup of medulloblastomas not expressing ATOH1. <i>Neuro-Oncology</i> , 2007 , 9, 298-307	1	28
46	Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. <i>Clinical Cancer Research</i> , 2007 , 13, 2606-13	12.9	123
45	The therapeutic potential of neural stem/progenitor cells in murine globoid cell leukodystrophy is conditioned by macrophage/microglia activation. <i>Neurobiology of Disease</i> , 2006 , 21, 314-23	7.5	42

44	Reclassification of oligoastrocytomas by loss of heterozygosity studies. <i>International Journal of Cancer</i> , 2006 , 119, 84-90	7.5	39
43	Brain engraftment and therapeutic potential of stem/progenitor cells derived from mouse skin. <i>Journal of Gene Medicine</i> , 2006 , 8, 506-13	3.5	19
42	Expression studies in gliomas and glial cells do not support a tumor suppressor role for LGI1. <i>Neuro-Oncology</i> , 2006 , 8, 96-108	1	21
41	Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. <i>Cancer Research</i> , 2006 , 66, 10247-52	10.1	201
40	Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5223-33	2.2	187
39	Salvage treatment for childhood ependymoma after surgery only: Pitfalls of omitting "at once" adjuvant treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 65, 1440-5	4	31
38	Instability of mitochondrial DNA and MRI and clinical correlations in malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2005 , 74, 87-9	4.8	23
37	KLF6 is not the major target of chromosome 10p losses in glioblastomas. <i>International Journal of Cancer</i> , 2004 , 111, 640-1	7.5	27
36	Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma. <i>Molecular Cancer</i> , 2004 , 3, 25	42.1	53
35	Expression of MATH1, a marker of cerebellar granule cell progenitors, identifies different medulloblastoma sub-types. <i>Neuroscience Letters</i> , 2004 , 370, 180-5	3.3	45
34	The potential of stem cells for the treatment of brain tumors and globoid cell leukodystrophy. <i>Cytotechnology</i> , 2003 , 41, 93-101	2.2	1
33	The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines. <i>Oncogene</i> , 2003 , 22, 2581-91	9.2	57
32	Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. <i>Annals of Neurology</i> , 2002 , 52, 842-5	9.4	29
31	Different simian virus 40 genomic regions and sequences homologous with SV40 large T antigen in DNA of human brain and bone tumors and of leukocytes from blood donors. <i>Cancer</i> , 2002 , 94, 1037-1048	6.4	64
30	Different simian virus 40 genomic regions and sequences homologous with SV40 large T antigen in DNA of human brain and bone tumors and of leukocytes from blood donors. <i>Cancer</i> , 2002 , 94, 1037-48	6.4	24
29	Gene therapy of glioblastomas: from suicide to homicide. <i>Progress in Brain Research</i> , 2001 , 132, 711-9	2.9	4
28	Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours. <i>Cytokine</i> , 2001 , 15, 27-38	4	28
27	Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats. <i>Journal of Neurosurgery</i> , 2000 , 92, 419-27	3.2	53

26	Gene therapy of experimental brain tumors using neural progenitor cells. <i>Nature Medicine</i> , 2000 , 6, 447-50.5	414
25	A recurrent 19q11-12 breakpoint suggested by cytogenetic and fluorescence in situ hybridization analysis of three glioblastoma cell lines. <i>Cancer Genetics and Cytogenetics</i> , 1999 , 110, 82-6	5
24	Identification of PTEN-related sequences in glioma cells and in non-neoplastic cell lines. <i>Cancer Letters</i> , 1999 , 138, 1-4	9.9 3
23	PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas. <i>Oncogene</i> , 1998 , 16, 541-5	9.2 72
22	Retroviral-mediated transfer of the galactocerebrosidase gene in neural progenitor cells. <i>NeuroReport</i> , 1998 , 9, 3823-7	1.7 24
21	IL-4 gene transfer for the treatment of experimental gliomas. <i>Advances in Experimental Medicine and Biology</i> , 1998 , 451, 315-21	3.6 6
20	Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. <i>Human Gene Therapy</i> , 1997 , 8, 1345-53	4.8 59
19	Gene transfer of suicide genes for the treatment of malignant gliomas: efficacy, limitations, and perspectives for a combined immunotherapy. <i>Acta Neurochirurgica Supplementum</i> , 1997 , 68, 100-4	1.7 2
18	Redefinition of the coding sequence of the MXI1 gene and identification of a polymorphic repeat in the 3' non-coding region that allows the detection of loss of heterozygosity of chromosome 10q25 in glioblastomas. <i>Human Genetics</i> , 1995 , 95, 709-11	6.3 20
17	The "bystander effect": association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. <i>Human Gene Therapy</i> , 1995 , 6, 763-72	4.8 123
16	Carnitine palmitoyltransferase II deficiency: structure of the gene and characterization of two novel disease-causing mutations. <i>Human Molecular Genetics</i> , 1995 , 4, 19-29	5.6 83
15	Absence of mutations and identification of two polymorphisms in the SSCP and sequence analysis of p21CKI gene in malignant gliomas. <i>International Journal of Cancer</i> , 1995 , 62, 115-7	7.5 17
14	Identification of 5' regulatory regions of the human carnitine palmitoyltransferase II gene. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1994 , 1219, 237-40	11
13	p53 mutations and microsatellite analysis of loss of heterozygosity in malignant gliomas. <i>Cancer Genetics and Cytogenetics</i> , 1994 , 74, 139-43	11
12	Increasing complexity of the karyotype in 50 human gliomas. Progressive evolution and de novo occurrence of cytogenetic alterations. <i>Cancer Genetics and Cytogenetics</i> , 1994 , 75, 77-89	45
11	Assignment of the gene encoding the beta-subunit of the electron-transfer flavoprotein (ETFB) to human chromosome 19q13.3. <i>Genomics</i> , 1994 , 19, 177-9	4.3 9
10	Molecular cloning of cDNAs encoding human carnitine acetyltransferase and mapping of the corresponding gene to chromosome 9q34.1. <i>Genomics</i> , 1994 , 23, 94-9	4.3 19
9	Assignment of the human carnitine palmitoyltransferase II gene (CPT1) to chromosome 1p32. <i>Genomics</i> , 1994 , 24, 195-7	4.3 64

8	cDNA cloning and mitochondrial import of the beta-subunit of the human electron-transfer flavoprotein. <i>FEBS Journal</i> , 1993 , 213, 1003-8		39
7	Molecular characterization of inherited carnitine palmitoyltransferase II deficiency. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992 , 89, 8429-33	11.5	138
6	Localization of the human gene for carnitine palmitoyltransferase to 1p13-p11 by nonradioactive in situ hybridization. <i>Genomics</i> , 1992 , 13, 1372-4	4.3	8
5	cDNA cloning, sequence analysis, and chromosomal localization of the gene for human carnitine palmitoyltransferase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 661-5	11.5	129
4	Isolation and sub-chromosomal localization of a DNA fragment of the human choline acetyltransferase gene. <i>Neuroscience Letters</i> , 1991 , 132, 191-4	3.3	9
3	Purification and properties of carnitine acetyltransferase from human liver. <i>FEBS Journal</i> , 1990 , 189, 539-46		37
2	Substrate stereochemistry of isovaleryl-CoA dehydrogenase. <i>Bioorganic Chemistry</i> , 1986 , 14, 170-175	5.1	5
1	Substrate stereochemistry of 2-methyl-branched-chain acyl-CoA dehydrogenase: elimination of one hydrogen each from (pro-2S)-methyl and alpha-methine of isobutyryl-CoA. <i>BBA - Proteins and Proteomics</i> , 1986 , 873, 308-11		1